Biosimilars fail to deliver on insulin pricing: Bowing to political and public pressure, insulin makers have slashed their prices. So far, insulin biosimilars haven't had much of an effect on prices.

PRICES; INSULIN; BIOSIMILARS; INSULIN derivatives; MEDICARE Part D; MEDICALLY uninsured persons

The article offers information about lower biologics prices, particularly in the case of insulin products, where Medicare and the dominant insulin producers have announced price cuts and caps on out-of-pocket costs. It discusses the impact on individuals with diabetes, the need for affordable access to insulin, and the potential role of biosimilars in providing more cost-effective options.